{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Calcium&page=14", "query": { "intervention": "Calcium", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 2102, "total_pages": 211, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Calcium&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Calcium&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T09:06:09.930Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05203172", "title": "The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2022-07-05", "completion_date": "2032-06-30", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-18T09:06:09.930Z", "location_count": 18, "location_summary": "Phoenix, Arizona • Atlanta, Georgia • Boston, Massachusetts + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05203172" }, { "nct_id": "NCT00671944", "title": "Long-term Nutritional Intervention Study to Determine How Protein Affects Calcium Metabolism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Osteoporosis" ], "interventions": [ { "name": "Low protein diet", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "20 Years to 40 Years · Female only" }, "enrollment_count": 11, "start_date": "2003-05", "completion_date": "2010-04", "has_results": false, "last_update_posted_date": "2020-03-31", "last_synced_at": "2026-10-18T09:06:09.930Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00671944" }, { "nct_id": "NCT01335399", "title": "Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Elotuzumab (BMS-901608; HuLuc63)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 748, "start_date": "2011-08-04", "completion_date": "2021-09-03", "has_results": true, "last_update_posted_date": "2022-09-30", "last_synced_at": "2026-10-18T09:06:09.930Z", "location_count": 88, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 70 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01335399" }, { "nct_id": "NCT00002816", "title": "Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "cytarabine", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "idarubicin", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "mesna", "type": "DRUG" }, { "name": "pegaspargase", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" }, { "name": "thioguanine", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "low-LET cobalt-60 gamma ray therapy", "type": "RADIATION" }, { "name": "low-LET electron therapy", "type": "RADIATION" }, { "name": "low-LET photon therapy", "type": "RADIATION" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "20 Years", "sex": "ALL", "summary": "Up to 20 Years" }, "enrollment_count": 120, "start_date": "1996-12", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2013-08-22", "last_synced_at": "2026-10-18T09:06:09.930Z", "location_count": 30, "location_summary": "Long Beach, California • Los Angeles, California • Orange, California + 23 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002816" }, { "nct_id": "NCT05977998", "title": "A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Carcinomatosis" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Famotidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2023-09-08", "completion_date": "2030-10-31", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-18T09:06:09.930Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05977998" }, { "nct_id": "NCT00072514", "title": "Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Testicular Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2003-08", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2017-06-29", "last_synced_at": "2026-10-18T09:06:09.930Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00072514" }, { "nct_id": "NCT02589600", "title": "Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Osteoporotic Fractures", "Osteoporosis, Postmenopausal" ], "interventions": [ { "name": "Zoledronic acid", "type": "DRUG" }, { "name": "vitamin D", "type": "DIETARY_SUPPLEMENT" }, { "name": "calcium", "type": "DIETARY_SUPPLEMENT" }, { "name": "Saline", "type": "OTHER" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Susan L. Greenspan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "FEMALE", "summary": "65 Years and older · Female only" }, "enrollment_count": 310, "start_date": "2016-01", "completion_date": "2022-06-22", "has_results": true, "last_update_posted_date": "2023-09-26", "last_synced_at": "2026-10-18T09:06:09.930Z", "location_count": 1, "location_summary": "New Kensington, Pennsylvania", "locations": [ { "city": "New Kensington", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02589600" }, { "nct_id": "NCT04608344", "title": "Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Pravastatin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Filgotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 27, "start_date": "2020-11-04", "completion_date": "2021-01-13", "has_results": true, "last_update_posted_date": "2022-06-14", "last_synced_at": "2026-10-18T09:06:09.930Z", "location_count": 1, "location_summary": "Saint Paul, Minnesota", "locations": [ { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04608344" }, { "nct_id": "NCT02186834", "title": "Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Liposomal doxorubicin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2014-09-23", "completion_date": "2018-03-14", "has_results": true, "last_update_posted_date": "2023-01-04", "last_synced_at": "2026-10-18T09:06:09.930Z", "location_count": 2, "location_summary": "Tampa, Florida • Detroit, Michigan", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02186834" }, { "nct_id": "NCT00869232", "title": "UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Velcade", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Thalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Adriamycin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 90, "start_date": "2008-10", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-18T09:06:09.930Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00869232" } ] }